ifinatamab – Talk Bio

Daiichi and Merck’s Lung Cancer ADC Achieves 48% Response Rate in Pivotal Trial

3 days ago talkbio0Tagged Accelerated, Antibody-Drug Conjugates, Approved, Breakthrough Therapy, CD276 gene, Co., Daiichi, Deruxtecan, Frequency of Responses, IDeate-Lung01, Identifier, ifinatamab, Overall Survival, Progression-Free Survival, Sankyo, Small cell carcinoma of lung, therapeutic autologous dendritic cells, United States Food and Drug Administration

Daiichi Sankyo; Merck & Co.; ifinatamab deruxtecan; I-DXd; B7-H3; antibody-drug conjugate; ADC; small cell lung cancer; SCLC; IDeate-Lung01; objective response rate; accelerated approval; progression-free survival; overall survival; FDA Breakthrough Therapy Designation

WCLC24: Merck & Daiichi Sankyo’s ADC Shows Promising Results in Small Cell Lung Cancer

1 year ago talkbio0Tagged Antibody-Drug Conjugates, Co., Daiichi, Deruxtecan, DXd, ifinatamab, Sankyo, Small cell carcinoma of lung, Technology, therapeutic autologous dendritic cells, WCLC24

WCLC24, Merck & Co., Daiichi Sankyo, ADC (Antibody Drug Conjugate), SCLC (Small Cell Lung Cancer), Ifinatamab Deruxtecan, DXd ADC Technology

Promising Phase 2 Results for Ifinatamab Deruxtecan in Small Cell Lung Cancer

1 year ago talkbio0Tagged Cell Lung Cancer, Daiichi, Deruxtecan, ifinatamab, Phase 2 trial, Sankyo, Small, Technology, therapeutic autologous dendritic cells

Ifinatamab Deruxtecan, Small Cell Lung Cancer, Phase 2 Trial, ADC Technology, Daiichi Sankyo, Merck